Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

SELLASs unusually large ASH 2026 exhibit and the unresolved REGAL Phase 3 event milestone are driving discussion, with traders also watching for SLS009 updates. Some interpret the booth and company silence as signs of favorable data or a potential buyout, while skeptics say those are unconfirmed assumptions and the trial results remain unknown.

Traders are widely speculating that Johnson & Johnson could acquire Sellas Life Sciences, citing perceived oncology fit and Sellass approaching REGAL Phase 3 AML readout; no deal has been confirmed, and some posters caution against treating the social-media clues as evidence. J&Js upcoming quarterly report is also on traders radar.

ICPs recent rebound and breakout attempt are drawing attention, with traders split between bullish momentum and concern that the token may again fail at resistance. The longer-term debate centers on its decentralized cloud and AI infrastructure potential versus weak adoption and persistent selling pressure.

PEPE is drawing attention for choppy, mostly range-bound trading after a volatile rebound, with traders repeatedly describing consolidation around a key level. Bulls see the holding pattern as a possible setup for another leg higher, while skeptics warn that brief pops are being sold and could fade.

Record-high refining margins, especially for diesel and other distillates, are the dominant focus, with traders linking tight refined-fuel supply and refinery constraints to MPCs strong run and repeated highs. Sentiment is split between bullishness on continued margin strength and concerns that elevated margins are already priced in and could fade, prompting profit-taking and caution about the stocks sharp rally.

The rebound is being linked to TD Cowen maintaining its Buy rating despite trimming its price target. Traders remain divided after Sezzles strong Q2 results and raised full-year outlook failed to prevent a sharp selloff: bulls call the decline excessive, while skeptics point to valuation, slower expected second-half growth, and margin pressure from higher credit costs.

Mercks BRUNELLO study results for its Wnt-pathway drug remigromig have traders looking for validation of Surrozens Wnt-based eye-drug pipeline; they also cite FDA clearance of SZN-8141s IND and the related financing milestone. Reactions are split between optimism about the mechanism and possible strategic interest, and concern that Surrozen has no human efficacy data yet and faces dilution from discounted financing and potential share sales.

Chewys post-Q2 selloff is the main focus, with traders pointing to slower organic growth, flat gross margins and weaker free cash flow despite raised full-year guidance; analyst concerns about muted growth added pressure. Bulls view the decline as an overreaction and cite market-share gains and buybacks, while bears question the growth and cash-flow outlook.

Exchange delisting and trading-pair removal concerns are fueling bearish discussion, though traders disagree over whether these changes reflect broader risk or routine consolidation. Bulls point to reported JasmyChain activity and ecosystem development, while skeptics argue that meaningful adoption and token demand remain unproven.

GameStops nearly 10% stake in eBay and its rejected takeover bid dominate discussion, with traders speculating about a renewed offer, board influence, or a partnership. Some expect the stake to unlock value, while skeptics question the deals feasibility and warn of financing and dilution risks.